Showing results (11-20 of 107) with videos related to
Sort By:
Pageof 11
Cancer Immunology Research|August 10, 2018
Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesKarl R VanDerMeid, Michael R Elliott, Andrea M Baran, et al.Clinical Lymphoma, Myeloma & Leukemia|May 1, 2016
Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin LymphomaPatrick M Reagan, Andrea Baran, Jennifer L Kelly, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphomaJames M Cleary, Scott Rodig, Paul M Barr, et al.Clinical Lymphoma, Myeloma & Leukemia|September 29, 2018
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin LymphomaRachel J David, Andrea Baran, Kah Poh Loh, et al.Clinical Lymphoma, Myeloma & Leukemia|June 10, 2023
Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma PopulationKriti Thapa, Myla Strawderman, Patrick M Reagan, et al.Blood Advances|January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaDanielle S Wallace, Clive S Zent, Andrea M Baran, et al.Clinical Immunology (Orlando, Fla.)|January 31, 2012
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletionPaul M Barr, Chungwen Wei, James Roger, et al.Leukemia & Lymphoma|March 10, 2020
Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatmentAnnaLynn M Williams, Edwin van Wijngaarden, Christopher L Seplaki, et al.Leukemia Research|July 14, 2018
Management of melanoma in patients with chronic lymphocytic leukemiaWilliam J Archibald, Philip J Meacham, AnnaLynn M Williams, et al.Journal of Geriatric Oncology|March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailtyPatrick M Reagan, Allison Magnuson, Craig A Portell, et al.Pageof 11